WuXi Biologics (Cayman) Inc. (WUXIBIO) cash flow statement

HKSE · Healthcare · Biotechnology · 14,705 employees · CEO Zhisheng Chen

Price: HK$44.60 +0.27%
Market cap: HK$184B
Enterprise value: CN¥149B
Last report: Q2 '26 filed 2026-06-30
Next report: 2027-03-23

In Q2 '26 WuXi Biologics (Cayman) Inc. (WUXIBIO) generated CN¥4.46B of operating cash flow, invested CN¥0 in capital expenditure and kept CN¥1.63B of free cash flow. Over the last two half-years free cash flow was CN¥4.42B.

Cash flow

Cash flow	Q4 '20	Q2 '21	Q4 '21	Q2 '22	Q4 '22	Q2 '23	Q4 '23	Q2 '24	Q4 '24	Q2 '25	Q4 '25	Q2 '26
Operating
Net income	CN¥953M	CN¥1.84B	CN¥1.55B	CN¥3.47B	CN¥1.89B	CN¥1.7B	CN¥1.7B	CN¥1.5B	CN¥3.34B	CN¥2.34B	CN¥2.53B	CN¥2.44B
Depreciation & amortization	CN¥246M	CN¥336M	CN¥372M	CN¥490M	CN¥301M	CN¥662M	CN¥720M	CN¥784M	CN¥858M	CN¥860M	CN¥888M	CN¥938M
Stock-based compensation	CN¥156M	CN¥223M	CN¥355M	CN¥600M	CN¥697M	CN¥637M	CN¥637M	CN¥690M	CN¥525M	CN¥469M	CN¥0	CN¥455M
Deferred income tax	CN¥2.32B	CN¥0	CN¥0	-CN¥1.3B	CN¥1.3B	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0
Change in working capital	-CN¥2.1B	CN¥0	-CN¥2.78B	CN¥1.12B	-CN¥2.1B	-CN¥448M	-CN¥448M	CN¥0	-CN¥801M	CN¥0	CN¥0	CN¥0
Other non-cash items	-CN¥118M	-CN¥1.6B	CN¥3.14B	-CN¥2.93B	CN¥2B	-CN¥217M	-CN¥275M	-CN¥1.67B	-CN¥2.76M	-CN¥1.86B	CN¥1.18B	CN¥624M
Operating cash flow	CN¥1.45B	CN¥798M	CN¥2.63B	CN¥1.46B	CN¥4.08B	CN¥2.33B	CN¥2.33B	CN¥1.3B	CN¥3.92B	CN¥1.81B	CN¥4.6B	CN¥4.46B
Investing
Capital expenditure	-CN¥3.11B	-CN¥4.07B	-CN¥2.43B	-CN¥2.68B	-CN¥3.18B	-CN¥2.02B	-CN¥2.02B	-CN¥1.87B	-CN¥2.06B	-CN¥1.9B	-CN¥1.86B	CN¥0
Acquisitions	-CN¥155M	-CN¥2.04B	-CN¥145M	-CN¥130M	-CN¥1.04M	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥1.28B	CN¥0
Purchases of investments	CN¥0	CN¥0	CN¥0	-CN¥10.8B	CN¥0	-CN¥7.54B	-CN¥7.54B	CN¥0	-CN¥11.4B	CN¥0	-CN¥7.09B	CN¥0
Sales / maturities of investments	CN¥0	CN¥0	CN¥0	CN¥10.5B	CN¥0	CN¥7.82B	CN¥7.82B	CN¥0	CN¥10.9B	CN¥0	CN¥4.9B	CN¥0
Other investing	CN¥81.7M	-CN¥1.63B	CN¥720M	CN¥738M	-CN¥361M	CN¥131M	CN¥131M	CN¥1.48B	-CN¥961M	CN¥1.36B	CN¥66.8M	-CN¥2.35B
Investing cash flow	-CN¥3.19B	-CN¥7.74B	-CN¥1.86B	-CN¥2.36B	-CN¥3.55B	-CN¥1.61B	-CN¥1.61B	-CN¥383M	-CN¥3.56B	-CN¥538M	-CN¥2.7B	-CN¥2.35B
Financing
Net debt issued / repaid	CN¥0	CN¥439M	-CN¥504M	-CN¥295M	-CN¥228M	-CN¥409M	-CN¥409M	-CN¥69.5M	CN¥490M	CN¥2.09M	-CN¥1.65B	-CN¥750M
Share buybacks	CN¥0	CN¥0	-CN¥2.52B	-CN¥691M	-CN¥2.11B	-CN¥458M	-CN¥458M	-CN¥1.23B	-CN¥532M	-CN¥1.03B	-CN¥555M	-CN¥1.31B
Other financing (incl. tax on vested shares)	CN¥5.52B	CN¥11.2B	-CN¥489M	CN¥767M	-CN¥259M	CN¥1.85B	CN¥3.02B	-CN¥172M	-CN¥1.25B	-CN¥56M	-CN¥98.5M	-CN¥66.7M
Financing cash flow	CN¥5.52B	CN¥11.2B	-CN¥3.01B	-CN¥219M	-CN¥2.37B	CN¥981M	CN¥2.15B	-CN¥1.48B	-CN¥1.27B	-CN¥1.09B	-CN¥1.01B	-CN¥2.06B
Summary
FX effect on cash	-CN¥401M	-CN¥86.2M	-CN¥45.3M	CN¥256M	CN¥94.3M	-CN¥63M	-CN¥63M	CN¥39.7M	CN¥44.3M	-CN¥23.1M	CN¥18.5M	-CN¥6.17M
Net change in cash	CN¥1.69B	CN¥233M	-CN¥1.14B	-CN¥2.61B	-CN¥870M	CN¥3.27B	CN¥3.27B	-CN¥258M	CN¥8.54B	CN¥8.44B	CN¥904M	CN¥31.8M
Free cash flow (OCF - capex)	-CN¥1.66B	-CN¥3.28B	CN¥199M	-CN¥1.23B	CN¥900M	CN¥219M	CN¥219M	-CN¥565M	CN¥1.85B	-CN¥93.7M	CN¥2.79B	CN¥1.63B
Interest paid	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥91.5M	CN¥0	CN¥0

Cash flow	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Operating
Net income	CN¥176M	CN¥304M	CN¥738M	CN¥1.13B	CN¥1.97B	CN¥3.99B	CN¥4.42B	CN¥3.4B	CN¥4.83B	CN¥4.91B
Depreciation & amortization	CN¥93.2M	CN¥123M	CN¥144M	CN¥221M	CN¥303M	CN¥482M	CN¥801M	CN¥1.17B	CN¥1.44B	CN¥1.72B
Stock-based compensation	CN¥47.6M	CN¥65.1M	CN¥128M	CN¥204M	CN¥284M	CN¥532M	CN¥1.3B	CN¥1.27B	CN¥1.22B	CN¥955M
Deferred income tax	CN¥0	CN¥0	CN¥0	-CN¥64.5M	-CN¥222M	-CN¥567M	CN¥0	CN¥0	CN¥0	CN¥0
Change in working capital	-CN¥206M	-CN¥149M	-CN¥246M	-CN¥216M	-CN¥367M	-CN¥963M	-CN¥974M	-CN¥896M	-CN¥801M	-CN¥1.69B
Other non-cash items	-CN¥28.2M	CN¥18.2M	-CN¥2.52M	-CN¥63.3M	-CN¥82.8M	-CN¥45.1M	-CN¥1.57M	-CN¥279M	-CN¥1.47B	CN¥488M
Operating cash flow	CN¥81.9M	CN¥360M	CN¥762M	CN¥1.21B	CN¥1.88B	CN¥3.43B	CN¥5.54B	CN¥4.67B	CN¥5.22B	CN¥6.39B
Investing
Capital expenditure	-CN¥429M	-CN¥688M	-CN¥1.83B	-CN¥3.23B	-CN¥6.02B	-CN¥6.52B	-CN¥5.87B	-CN¥4.05B	-CN¥3.93B	-CN¥3.64B
Acquisitions	CN¥0	CN¥17.1M	CN¥490M	-CN¥301M	-CN¥155M	-CN¥2.54B	-CN¥131M	CN¥0	CN¥0	CN¥4.07B
Purchases of investments	CN¥0	-CN¥2.82B	-CN¥1.06B	-CN¥4.64B	-CN¥20.4B	-CN¥59.3B	-CN¥10.8B	-CN¥15.1B	-CN¥11.4B	-CN¥13.2B
Sales / maturities of investments	CN¥26.7M	CN¥1.28B	CN¥2.33B	CN¥3.91B	CN¥19.3B	CN¥58.2B	CN¥10.5B	CN¥15.6B	CN¥10.9B	CN¥9.38B
Other investing	-CN¥18.9M	CN¥6.59M	-CN¥353M	-CN¥230M	CN¥67.1M	CN¥513M	CN¥378M	CN¥262M	CN¥524M	CN¥53.8M
Investing cash flow	-CN¥421M	-CN¥2.21B	-CN¥416M	-CN¥4.49B	-CN¥7.22B	-CN¥9.6B	-CN¥5.91B	-CN¥3.23B	-CN¥3.94B	-CN¥3.38B
Financing
Net debt issued / repaid	CN¥625M	-CN¥903M	CN¥0	CN¥1.91B	CN¥870M	-CN¥147M	-CN¥295M	-CN¥818M	CN¥490M	-CN¥1.63B
Share buybacks	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	-CN¥2.52B	-CN¥2.8B	-CN¥917M	-CN¥1.77B	-CN¥1.54B
Other financing (incl. tax on vested shares)	-CN¥293M	-CN¥441M	-CN¥18.6M	-CN¥93.4M	CN¥46.3M	-CN¥162M	CN¥508M	CN¥3.7B	-CN¥1.49B	-CN¥104M
Financing cash flow	CN¥333M	CN¥2.23B	CN¥3.21B	CN¥5.41B	CN¥6.57B	CN¥8.21B	-CN¥2.59B	CN¥1.96B	-CN¥2.75B	-CN¥1.95B
Summary
FX effect on cash	CN¥17.3M	-CN¥41.6M	CN¥28.2M	-CN¥5.87M	-CN¥340M	-CN¥132M	CN¥350M	-CN¥126M	CN¥84M	CN¥242M
Net change in cash	CN¥10.9M	CN¥335M	CN¥3.58B	CN¥2.12B	CN¥890M	CN¥1.91B	-CN¥2.61B	CN¥3.27B	-CN¥1.39B	CN¥1.29B
Free cash flow (OCF - capex)	-CN¥347M	-CN¥327M	-CN¥1.07B	-CN¥2.03B	-CN¥4.14B	-CN¥3.09B	-CN¥327M	CN¥437M	CN¥1.29B	CN¥2.8B

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in CNY.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Income statementRevenue, costs, operating income, net income and EPSOpen Balance sheetCash, investments, assets, debt, liabilities and equityOpen

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in CNY as reported; price and market cap in HKD.